Jul 19 2010
"Amira Pharmaceuticals, Inc. announced today that its FLAP (5-lipoxygenase-activating protein) program, which is partnered with GlaxoSmithKline, has achieved two clinical development milestones."
These milestones are related to the successful progression of the program to Phase 2 studies, which explore the use of the Amira discovered FLAP inhibitor in patients suffering from asthma.
"These milestones demonstrate the success of our partnership with GSK as well as the need for new therapies for asthma sufferers." said Hari Kumar, Chief Business Officer. "These milestone payments enable Amira to continue to fund our highly productive research and development opportunities well into the future."
Source:
Amira Pharmaceuticals, Inc.
University of Arizona receives $3.4 million grant to expand asthma inhaler program in schools